Product Description
The MediFocus Guidebook on Chronic Lymphocytic Leukemia is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Chronic Lymphocytic Leukemia, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Chronic Lymphocytic Leukemia, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks. This Guidebook was updated on May 27, 2010. ... Read more

Product Description
Childhood leukemias represent nearly one third of all cancers in children and present a unique challenge to oncologists, pediatricians, hematologists, and other health professionals. Ching-Hon Pui has assembled an expert team of authors to develop the most comprehensive, clinically-oriented, and authoritative reference dedicated to these diseases. The volume moves from the laboratory bench to the patient bedside in four easily-accessible sections. Fully referenced and up-to-date, it is an absolute 'must-have' for any physician or investigator who deals with leukemias in childhood. ... Read more

Product Description
For the most honest, objective opinion, HealthScouter provides a patient's view of the most common medical problems. Including hundreds of quotes, questions, and answers from patients themselves, this guide provides comprehensive information about a single condition for from perspective that matters: the patient's perspective. Understand how current patients approach their medical challenges, and help overcome your own. This reference will help you see through obscure medical jargon and limited treatment options and empower you to better understand the issues that really matter: Diagnosis + Symptoms + What to Expect + Treatment Options + Medical Terminology ... Read more

Product Description

This is a timely compilation of new concepts in the molecular pathogenesis and molecular therapy of acute myelogenous leukemia (AML). The focus is on selected critical molecular determinants of AML pathogenesis and pathophysiology and the exploitation of these factors by diverse therapeutic agents and modalities. There is an emphasis throughout on the bidirectional flow of knowledge between the clinical and laboratory arenas.

Product Description

Chronic Myeloid Leukemia (CML) remains a key model for the improved understanding of the pathophysiology of a malignancy at a molecular level and has been used by researchers to develop a variety of therapies and therapeutic assessment methods. This concise, readable guide assembles and synthesizes the latest developments and trends in the treatment of CML and provides an authoritative and convenient summary of the latest progress in imatinib trials, the molecular monitoring of CML responses, and the engineering of new therapies to overcome resistance and improve patient care.

Providing critical insight and exploration of models that will enhance the cancer community at large, this source:

• stands as the only source to focus on post-Gleevec developments in CML therapeutics
• collects information from the forefront of the field—helping busy clinicians make informed management decisions
• supplies critical research from recognized opinion leaders on the topic
• provides an overview of the current status of new transplant modalities
• contains a vivid selection of color photographs

Product Description
Toxic waste, contaminated water, cancer clustersthese phrases suggest deception and irresponsibility. But more significantly, they are watchwords for a growing struggle between communities, corporations, and government. In No Safe Place, sociologists, public policy professionals, and activists will learn how residents of Woburn, Massachusetts discovered a childhood leukemia cluster and eventually sued two corporate giants.Their story gives rise to questions important to any concerned citizen:What kind of government regulatory action can control pollution?Just how effective can the recent upsurge of popular participation in science and technology be? Phil Brown, a medical sociologist, and Edwin Mikkelsen, psychiatric consultant to the plaintiffs, look at the Woburn experience in light of similar cases, such as Love Canal, in order to show that toxic waste contamination reveals fundamental flaws in the corporate, governmental, and scientific spheres.The authors strike a humane, constructive note amidst chilling odds, advocating extensive lay involvement based on the Woburn model of civic action. Finally, they propose a safe policy for toxic wastes and governmental/corporate responsibility. Woburn, the authors predict, will become a code word for environmental struggles. ... Read more

Product Description
Focuses on techniques to diagnose precise defects in genetically unstable, evolving leukemic populations of neoplastic hematopoietic cells, highlighting findings on the molecular biology and clinical behavior of chronic myelogenous leukemia (CML). Covering the identification and characterization of ... Read more

Product Description
The current explosion of new areas of controversy in the treatment of acute lymphocytic leukemia in adults and young adults makes this comprehensive book a much needed reference for hematologists and oncologists.This book assembles leading authorities from around the globe to cover the full spectrum of ALL subtypes and their treatments.Specific topics of discussion include indications for allogeneic bone marrow transplant in first complete remission, the role of minimal residual disease in making treatment decisions, the treatment of young adults, and the treatment of Philadelphia chromosome positive ALL with the advent of the tyrosine kinase inhibitors. This is the first book to focus exclusively on the adult ALL patient.It provides a complete overview of diagnosis, molecular pathogenesis, evaluation, and treatment for this important patient population. ... Read more

Product Description
Dr. Talpaz has assembled top experts to write state-of-the art reviews on the management of chronic myelogenous leukemia. Some of the articles that will be of most interest include  Selection of Therapy: Rational Decisions Based on Molecular Events; Is There a Potential Cure for CML in Current Therapies?; Hurdles Toward a Cure for CML: The CML Stem Cell; The CML Stem Cell in the Chronic and Advanced Disease; CML Disease Progression; Management of Ph+ ALL and CML Blast Crisis; BMT in CML in the Era of Targeted Therapy; Pharmacoeconomics: The Cost of Staying Alive; and The Significance of CML Prognostic Factors in the Era of Targeted Therapy. ... Read more

Customer Reviews (4)

great book
A fascinating and well wrtten accounting of the incredible story behind the conquering of much of childhood leukemia.These are real hero's stories.

Historical view pointbut cyto toxins are devistating & experimental.
As a mother of 3, one of which has ALL Acute Lymphoblastic leukaemia, and a researcher, I want parents to know that there is more out there than this author offers.The tragedy is a moral one, while they have been using our children as guinee pigs for 30 years they have also shut out all other promising research of less harmful treatments that have shown good results.Only "inefficent" cyto toxins have been promoted and invested in.Fishbowl mentality not serving humanity but serving Big Pharma profits.My 3yr old has nearly died from cyto toxic chemo and this treatment predisposes patients to multiple other cancers in future.Cyto-toxins may be an appropriate first aid but as a prolonged treatment they are harmful in hidden and devistating ways.Hippocrates said "first thout should do no harm", perhaps looking outside the square as they did to find quantum physics, would be more successful and less devistating to families.We have lost everything due to the treatment alone.Alternatives provide more promise and better results but people are frightened and guilted into taking chemo, by MDs,when there are more efficent treatments for the long term with less harmful side effects.THis publication is good for the historical point, showing the investment since the great wars in cyto-toxins.But many competing and more successful treatments have been suppressed due to this treatment.Interestingly chemo has extreemly poor results with any other cancer and yet it is used universally in all cancers.Not exactly commonsense. Multinationals suppress our technology to enable continued profit from fossil fuels and the same authorities suppress competing research in this industry because they don't want to lose market share or admitt the limitations of the cyto-toxic industry.Parents are not given choice in this treatment and the population based statistics used do not cater for individual needs.It has supprised me how little medical professionals know about cutting edge research and how quickly new breakthroughs get lost or dissapear.MD's are only as good as the information provided to them and can the source of information be trusted given the cold war approach to cyto-toxic alternatives.The fishy smell is the economics.Ignorance and economics are putting our children at risk in prevention and cure.A Fact.Cyto-toxins cannot proport to be a cure or miracle, too many children have died from cyto toxic effects and experimentation that continues today. THe crime is in not looking beyond the first aid approach, beyond cyto-toxins, to focus on harm minimisation and treatments that are more efficient than current drugs.THis book is written by someone that is entrenched in the fishbowl mentality and has only painted part of the historical picture.Again he is only as good as the information provided to him.I am a researcher, I know what I am speaking of.Bring parents choice and harm minimisation or get off the podium.It took Medical professionals 200 years before they allowed Vitamin c to become a mainstream treatment of scurvey, shunning the proporter as a quack.OUr children are still dying from ignorance in 2005.

Miracles and Medicine: One Parent's Introduction to Leukemia
I came across this book while sitting in my daughter's hospital room still inundated with the news that she had childhhod leukemia.It was there amid the pamphlets and literature that symbolized the "dump" our lives had just taken.

I picked it up one sleepless night and, by the time I finished, I knew that my duaghter had every chance of surviving.We faced her two and a half year treatment with a new understanding that we were members of a group of children, families, medical practitioners and researchers who make a difference.

That was five years ago.This book set the tone for our struggles and victories large and small.It gave us perspective. It gave us hope and it gave us gratitude for all of the efforts that, ulitmately, gave my daughter back to me -- healthy and strong.

History of treatment for childhood leukemia
Childhood leukemia survival rates have increased dramatically in the last 20 years and this book gives historical perspective of significant treatment breakthroughs and scientific developments through the stories of several doctors and researchers.Excellent reference book for students and researchers, less applicable for medical consumers who may find current treatment-oriented books more useful. ... Read more

Product Description

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.

Product Description
Written by international experts in the field, this new guideexamines cutting-edge clinical studies that investigate innovative therapies and related topics for leukemia and lymphoma including:

·tyrosine kinase inhibitors, histon deacetylase inhibitors, and farnesyl transferase inhibitors

·radioimmunotherapy, gene-directed therapy, and immunotherapy by vaccination

·monoclonal antibodies

·anti-angiogenesis approaches

·the concerns of conventional but novel anticancer agents

·modulation of classical multidrug resistance

·modulators of single agent drug resistance.

Innovative Leukemia and Lymphoma Therapy is the only comprehensive and up-to-date overview of the exciting new treatment modalities in leukemia and lymphoma in practice today ... Read more

Product Description
New treatments mean improved survival for many patients ... Read more

Product Description
This issue brings together a collection of over 30 outstanding contributions presented, covering the biology, clinical aspects and therapy of chronic lymphocytic leukemia. ... Read more

Product Description
While leukemia remains a life-threatening and debilitating form of cancer, recent advances have made treatment of this disease one of the greatest success stories in modern medicine. (20051001) ... Read more

Product Description
In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing.This book was created for medical professionals, students, and members of the general public who want to conduct medical research using the most advanced tools available and spending the least amount of time doing so. ... Read more